Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.46 |
| ▸ | MMP12 | P39900 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 2/20 | 0.46 |
| ▸ | MMP16 | P51512 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824347 | 1.00 | HTT (0.49) | HTTPTGS2CXCL8MMP2MMP9 | |
| SCHEMBL4825414 | 1.00 | HTT (0.49) | HTTPTGS2CXCL8MMP2MMP9 | |
| SCHEMBL15695565 | 0.88 | HTT (0.49) | HTTPTGS2CXCL8MMP2MMP9 | |
| SCHEMBL29144510 | 0.88 | HTT (0.49) | HTTPTGS2CXCL8MMP2MMP9 | |
| SCHEMBL27600698 | 0.85 | HTT (0.50) | HTTPTGS2CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2204495 | 0.84 | PTGS2 (0.56) | PTGS2CXCL8MMP2MMP9MMP8 | |
| SCHEMBL8945731 | 0.84 | CXCL8 (0.44) | HTTPTGS2CXCL8MMP2MMP9 | |
| SCHEMBL286787 | 0.82 | CXCL8 (0.43) | HTTPTGS2CXCL8MMP2MMP9 | |
| SCHEMBL7595932 | 0.82 | PGR (0.47) | HTTPTGS2PTGS1CYP2C9CYP2C19 | |
| SCHEMBL9780871 | 0.82 | HTT (0.51) | HTTPTGS2CXCL8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101380317-A | Pharmaceutical composition for relieving pruritus | CAYMAN ISLAND SHANGANSHENG DEV (CN) | 2009-03-11 | — | — | CN | claimed |
| CN-1911925-A | 3,4-dihydro-III 2 benzopyran-1 ketone kind compound, its preparation method and use | SHANGHAI INST OF MEDICINE CAS (CN) | 2007-02-14 | — | — | CN | claimed |
| CN-1425001-A | Process for preparing -2-acetylthio-3-phenylpropionic acid | DSM NV (NL) | 2003-06-18 | — | — | CN | claimed |
| EP-0328291-B1 | HALOGENATED POLYBUTADIENE SERIES ELASTOMERS, METHOD OF PRODUCING THE SAME, AND RUBBER COMPOSITIONS FOR TIRES CONTAINING THE ELASTOMER | Bridgestone Corporation (JP) | 1992-04-29 | — | — | EP | claimed |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-09-02 | — | — | US | disclosed |
| EP-4010076-B1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-01-17 | — | — | EP | disclosed |
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-10-06 | — | — | US | disclosed |
| EP-4010076-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028336-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-02-18 | — | — | WO | disclosed |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2946792-A1 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA; | Resilio Company Limited (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-5240938-A | Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring | MERCK & CO., INC. (US) | 1993-08-31 | — | — | US | disclosed |
| EP-0517812-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO. INC. (US) | 1992-12-16 | — | — | EP | disclosed |
| WO-1991011999-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| EP-0255178-A2 | Process for preparing hetero aryl and aryl alkanoic acids | Nobel Chemicals AB (SE) | 1988-02-03 | — | — | EP | disclosed |
| CN-86108331-A | The halogenated radioactive small molecule of labelled protein | — | 1987-11-04 | — | — | CN | disclosed |
| US-4290959-A | Preparation of propylene oxide | HALCON RESEARCH AND DEVELOPMENT CORP. (US) | 1981-09-22 | — | — | US | disclosed |
| US-4169809-A | Extractive purification of carboxylic acids containing monovalent and trivalent thallium carboxylates | HALCON RESEARCH & DEVELOPMENT CORPORATION (US) | 1979-10-02 | — | — | US | disclosed |
| US-4166097-A | CARBOXYLIC ACID | HALCON RESEARCH & DEVELOPMENT CORPORATION (US) | 1979-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | HTT 459/4885PTGS2 240/4885CXCL8 2614/4885 |
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | HTT 1755/4885PTGS2 2613/4885CXCL8 3450/4885 |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | HTT 1755/4885PTGS2 2613/4885CXCL8 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.